Jade Biosciences, Inc. (JBIO) IPO — S-1 Filing, Stock & Insider Activity

Jade Biosciences, Inc. IPO — Status & S-1 Filing

Ticker: JBIO
Status: Registered — S-1 filed with the SEC
S-1 filed: 2025-11-14
Exchange: NASDAQ
Expected price range: not yet disclosed (set in a later S-1/A or pricing amendment)
Shares offered: 43,947,116
SEC CIK: 0001798749 · View the S-1 on SEC EDGAR →

Track every registration update on the InsiderAlpha IPO tracker.

Updated Jul 16, 2026 · Last SEC filing 2026-06-27

Jade Biosciences, Inc. (JBIO) has filed 6 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-06-27. 7 Form 8-K material event filings were reported by JBIO in the last 90 days. InsiderAlpha tracks every JBIO SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About Jade Biosciences, Inc. (JBIO)

SIC classification	Pharmaceutical Preparations (SIC 2834)
SEC CIK	0001798749

90-Day SEC Filing Activity

Form 4 filings (90d)	6
Form 8-K filings (90d)	7
Latest Form 4 filing	2026-06-27

Recent JBIO Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-02-12	Dahms Bradford D.	Chief Financial Officer	A — Grant or award	37.8K	$0.00	—	SEC
2026-02-12	Balta Elizabeth	See Remarks	A — Grant or award	28.1K	$0.00	—	SEC
2026-02-12	Frohlich Tom	Chief Executive Officer	A — Grant or award	78.8K	$0.00	—	SEC
2026-02-12	King Andrew James	See Remarks	A — Grant or award	41.2K	$0.00	—	SEC
2025-10-06	Fairmount Funds Management LLC	Director	A — Grant or award	1.33M	$9.14	$12.18M	SEC

All transactions sourced from SEC EDGAR Form 4 filings for Jade Biosciences, Inc. (JBIO). Updated in real time as new filings are submitted to the SEC.

Most-Active JBIO Insiders — Last 90 Days

Insider	Form 4 filings	Total transaction value
Fairmount Funds Management LLC	1	—
CAIN CHRISTOPHER W.	1	—
Eisner Mark	1	—
DOBMEIER ERIC	1	—
Klein Lawrence Otto	1	—

Recent JBIO Form 8-K Material Events

2026-07-01 — Item 1.01 [SEC]
2026-06-26 — Item 5.02, 7.01, 9.01 [SEC]
2026-06-11 — Item 5.03, 5.07, 9.01 [SEC]
2026-06-04 — Item 8.01, 9.01 [SEC]
2026-06-01 — Item 7.01, 8.01, 9.01 [SEC]

Recent Insider Filings

2026-06-27 — Eisner Mark (Insider)
2026-06-11 — CAIN CHRISTOPHER W. (Insider)
2026-06-11 — DOBMEIER ERIC (Insider)
2026-06-11 — Klein Lawrence Otto (Insider)
2026-06-11 — Lavelle Erin (Insider)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in JBIO insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

JBIO Insider Trading — FAQ

What is the latest insider trade for JBIO?: Jade Biosciences, Inc. (JBIO) had 6 insider filings in the last 90 days, with the most recent on 2026-06-27. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying JBIO stock?: 0 insider purchases of JBIO were filed in the last 90 days.
How many insiders are selling JBIO stock?: 0 insider sales of JBIO were filed in the last 90 days.
Where can I see JBIO SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every JBIO SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Related Companies — Recent Insider Activity

Learn More

Open the live JBIO dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.